What platinum/PARPi/DDR therapy should we give next?
Top 5 drug recommendations ranked by S/P/E framework. Mechanism-based matching with transparent scoring. Validated AUROC 0.70 (n=149).
Once you have CSI score, unlock drug recommendations and clinical trial matching. S/P/E framework (validated AUROC 0.70, n=149) ranks therapies by mechanism fit for DDR-targeted treatments.
The Problem: Generic Drug Ranking for DDR-Targeted Therapy
For patients with advanced, heavily pretreated cancer, clinicians need to know: ...
No Mechanism Understanding
Generic mutation lists don't explain why a DDR-targeted drug fits
No Transparent Reasoning
No clear scoring to understand why PARPi ranks higher than platinum for a specif
No Clinical Trial Matching
Missing mechanism-based trial matching means patients miss DDR-targeted combinat
The Solution: CSI-Powered Drug Recommendations with S/P/E Framework
Once you have CSI score, unlock drug recommendations and clinical trial matching
S/P/E Framework
Sequence (30%) + Pathway (40%) + Evidence (30%) for comprehensive drug ranking
Confidence & Tiers
Evidence tiers (Supported/Consider/Insufficient) with confidence scores and badg
Insights Integration
4 insights chips provide confidence lifts when biological signals align
How Level 2 Works
Four steps to unlock this capability
Take CSI Score from Level 1
Add Genomic Test Results (NGS)
Calculate S/P/E Scores
Rank Drugs and Match Clinical Trials
CSI in Action: Continuous Monitoring
See how CSI updates automatically as tumor evolves. Track chemosensitivity across treatment lines with real-time alerts when CSI drops below threshold.
Level 2: Genomic Monitoring
Add genomic testing to detect resistance mutations and find clinical trials
CSI Continuous Monitoring
Track CSI score updates as tumor evolves. Never miss a chemosensitivity change. • Patient AK
ChemoSensitivity Index
3/6/2026
Tumor Marker
2/28/2026
CT Scans
2/14/2026
Liquid Biopsy
3/6/2026
Clinical Trials
3/5/2026
Active Alerts & Insights
3 Active(1 locked at Level 3)CSI Score Decreased
Your CSI score dropped, meaning chemo is becoming less effective
CA-125 Plateau
Your CA-125 stopped declining and is staying flat
New Trial Match
A clinical trial that matches your specific tumor biology just opened
Next: Level 3 - Resistance Prediction
Get early warnings 3-6 weeks before imaging shows treatment failure
Level 2 Performance Metrics
Validated performance for this capability
Validation Status
Validated performance for this capability
Ready for Level 3?
What resistance class is active right now? Monitors 10 resistance classes validated across 680 patients from 6 independent datasets with temporal ctDNA modeling.